RxDoctor Payments Data

Sumeet Gupta, MD

Ophthalmology · Springfield, VANPI 1871971895

Payments from drug & device makers

$1,409in general payments, 2019–2025

Across 47 payments — averaging $29.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sight Sciences, Inc.$371
  • Alcon$293
  • AbbVie$229
  • Sun Pharmaceutical Industries Inc.$90
  • NEW World Medical,inc.$88
  • Glaukos Corporation$80
  • plus $257 from 7 others

What the payments were for

  • Food & beverage$1,409100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,409 in reported general payments places this provider in the 55th percentile of 509 ophthalmology providers in Virginia.

See all ophthalmology providers in Virginia

Medicare billing

Part B allowed, 2024
$389,641
Medicare patients
932
Services billed
2,918

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine25$35,219
LumiganBimatoprost44$25,396
RocklatanNetarsudil Mesylat/Latanoprost14$13,407
CombiganBrimonidine Tartrate/Timolol25$12,254
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat254$5,674
Alphagan PBrimonidine Tartrate15$5,656
Prednisolone Acetate107$4,893
Brimonidine Tartrate98$4,052
Latanoprost335$3,681
MoxifloxacinMoxifloxacin Hcl88$3,089
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol21$2,746
Travoprost11$2,507
Ketorolac Tromethamine88$2,013
Dorzolamide Hcl28$778
Timolol Maleate77$660

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan, Alphagan P$229$78,526109 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 509 ophthalmology providers in Virginia.

Other ophthalmology in Springfield

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →